1.17
前日終値:
$1.19
開ける:
$1.2
24時間の取引高:
85,792
Relative Volume:
0.08
時価総額:
$140.65M
収益:
$4.35M
当期純損益:
$-45.53M
株価収益率:
-1.0833
EPS:
-1.08
ネットキャッシュフロー:
$-44.79M
1週間 パフォーマンス:
-5.95%
1か月 パフォーマンス:
-22.04%
6か月 パフォーマンス:
+50.38%
1年 パフォーマンス:
+36.36%
Lucid Diagnostics Inc Stock (LUCD) Company Profile
LUCD を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
LUCD
Lucid Diagnostics Inc
|
1.18 | 140.65M | 4.35M | -45.53M | -44.79M | -1.08 |
![]()
ABT
Abbott Laboratories
|
133.47 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
105.34 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
391.21 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
85.90 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
77.06 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2021-12-27 | 開始されました | Ascendiant Capital Markets | Buy |
2021-11-08 | 開始されました | BTIG Research | Buy |
2021-11-08 | 開始されました | Cantor Fitzgerald | Overweight |
2021-11-08 | 開始されました | Needham | Buy |
Lucid Diagnostics Inc (LUCD) 最新ニュース
Lucid Diagnostics Holds Annual Stockholders Meeting - TipRanks
Leading California Hospital Network Launches Revolutionary 3-Minute Cancer Detection Test from Lucid Diagnostics - Stock Titan
119,887 Shares in Lucid Diagnostics Inc. (NASDAQ:LUCD) Acquired by Citadel Advisors LLC - Defense World
Ascendiant Capital Markets Issues Positive Forecast for Lucid Diagnostics (NASDAQ:LUCD) Stock Price - Defense World
Ascendiant Capital raises Lucid Diagnostics stock price target to $7.75 By Investing.com - Investing.com South Africa
Ascendiant Capital raises Lucid Diagnostics stock price target to $7.75 - Investing.com Australia
Lucid Diagnostics (LUCD) Stock Maintained at Buy by Ascendiant Capital | LUCD Stock News - GuruFocus
Lucid Diagnostics (LUCD) Target Price Increased by Ascendiant | - GuruFocus
Lucid Diagnostics Files For Offering Of 36 Million Shares Of Common Stock - MarketScreener
Pavmed's Veris Health Signs Long-Term Partnership Deal With Ohio State University Hospital - marketscreener.com
Lucid Diagnostics Enters $25M Sales Agreement - TipRanks
Lucid Diagnostics joins Russell 2000 and 3000 indexes - Mugglehead Magazine
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes - The Malaysian Reserve
Lucid Diagnostics to Join Russell 2000, Russell 3000 Indexes - marketscreener.com
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes By Investing.com - Investing.com South Africa
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes - Investing.com Australia
Lucid Diagnostics (LUCD) Joins Russell 2000 and Russell 3000 Indexes | LUCD Stock News - GuruFocus
Lucid Diagnostics (LUCD) Joins Russell 2000 and Russell 3000 Ind - GuruFocus
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.50 Consensus Price Target from Brokerages - Defense World
Certain Options of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - marketscreener.com
Certain Common Stock of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - marketscreener.com
Insider Buying: Dennis Matheis Acquires 350,000 Shares of Lucid Diagnostics Inc (LUCD) - GuruFocus
Certain Series B-1 Convertible Preferred Stock of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - MarketScreener
Lucid Diagnostics (LUCD) Director Acquires Significant Shares | - GuruFocus
Lucid Diagnostics (LUCD) Director Acquires Significant Shares | LUCD Stock News - GuruFocus
Lucid Diagnostics Joins Elite Russell Indexes, Opens Door to $10.6T Investment Pool - Stock Titan
Lucid Diagnostics Files Shelf Registration for Secondary Sale of 37 Million Shares by Convertible Note Holders - marketscreener.com
Lucid Diagnostics (LUCD) Files to Sell 36.98 Million Shares | LU - GuruFocus
Lucid Diagnostics Files Prospectus For Potential Offer, Sale From Time To Time Of Up To 37 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
Lucid Diagnostics (LUCD) Files to Sell 36.98 Million Shares | LUCD Stock News - GuruFocus
Lucid Diagnostics’ SWOT analysis: stock faces reimbursement hurdles amid market potential - Investing.com Nigeria
Cantor Fitzgerald maintains Lucid Diagnostics stock Overweight - Investing.com Australia
Cantor Fitzgerald maintains Lucid Diagnostics stock Overweight By Investing.com - Investing.com India
Lucid Diagnostics’ (LUCD) Buy Rating Reiterated at Needham & Company LLC - Defense World
Cantor Fitzgerald Reiterates “Overweight” Rating for Lucid Diagnostics (NASDAQ:LUCD) - Defense World
Lucid Diagnostics (LUCD) Stock Rating Reiterated by Cantor Fitzg - GuruFocus
Lucid Diagnostics signals expanded market reach and $41M pro forma cash following commercial and clinical advances - MSN
Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NUVB), Lucid Diagnostics (LUCD) and Arcellx Inc (ACLX) - The Globe and Mail
Lucid Diagnostics Reports Increased Losses Amid Revenue Decline - TipRanks
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates - MSN
Cantor maintains Lucid Diagnostics stock with $2 target after Q1 results - Investing.com Australia
Lucid Diagnostics (LUCD) Stock Rating Reiterated by Cantor Fitzgerald | LUCD Stock News - GuruFocus
Transcript : PAVmed Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
PAVmed Inc Q1 2025 Earnings: Revenue Surges to $0.8 Million, Bea - GuruFocus
PAVmed Provides Business Update and Reports First Quarter 2025 F - GuruFocus
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results | PAVM Stock News - GuruFocus
Lucid Diagnostics Inc (LUCD) 財務データ
収益
当期純利益
現金流量
EPS
Lucid Diagnostics Inc (LUCD) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Matheis Dennis | Director |
May 21 '25 |
Buy |
1.32 |
129,684 |
171,520 |
316,782 |
Matheis Dennis | Director |
May 22 '25 |
Buy |
1.32 |
33,218 |
43,795 |
350,000 |
大文字化:
|
ボリューム (24 時間):